PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTAN

Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immun...

Full description

Bibliographic Details
Published in:Revista do Instituto de Medicina Tropical de São Paulo
Main Authors: Angela Aparecida COSTA, Marta INENAMI, Edmundo JUAREZ, Pedro Dorlhiac LLACEN, Isaias RAW
Format: Article
Language:English
Published: Universidade de São Paulo (USP) 1997-01-01
Subjects:
Recombinant hepatitis B vaccine
Clinical trials
Adults
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651997000100008
Description
Summary:Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects)<br>Três doses de 10 µg da vacina recombinante contra hepatite B, produzida pelo Instituto Butantan, através de tecnologia própria, foram administradas numa população de adultos (idade média 30 anos), seguindo o esquema de imunização 0, 1 e 6 meses após a primeira dose. A avaliação clínica da vacina foi considerada satisfatória em termos de imunogenicidade (títulos dos anticorpos anti-HBs entre 17,5-29500 UI/1, soroconversão 95,3%) e reatividade (sem efeitos colaterais e sintomas clínicos relevantes)
ISSN:0036-4665
1678-9946

Similar Items